Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to explore different dosing levels and schedules of
entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms
of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy